The molecular mechanism of prognostic exacerbation by the addition of KIT mutations in CBF leukemia

核心结合因子（CBF）急性髓系白血病（AML）预后较好。然而，据报道，激活KIT突变与较高的复发风险和较短的生存期有关。本项目旨在阐明KIT突变对此类不利影响的分子机制。申请人解释，KIT突变通过诱导耐药基因和DNA修复相关基因的减少，导致CBF白血病预后不良。

Core binding factor (CBF) acute myeloid leukemia (AML) has a relatively favorable prognosis. However, activating KIT mutations are reported to be associated with higher risk of relapse and shorter survival. This project aims to clarify the molecular mechanism of such unfavorable effects by KIT mutations. The applicant explained that KIT mutations give poor prognosis to CBF leukemia through the induction of drug resistance genes and the reduction of DNA repair-related genes.